- My first article on Bionano Genomics was negative as the stock price did a meme-stock bounce far ahead of reality.
- I traded the stock below $1 hitting my short-term profit goal, then watched it spike into the teens, with some saying it would go to $100 a share.
- The share price now more accurately reflects further roll-out of the Saphyr system, revenues, risks going forward, and ongoing dilution.
- Instead of buying, I'm selling puts to reduce eventual cost basis while collecting premium. To me, this is a good balance vice buying shares outright.
For further details see:
I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics